A352770 Stock Overview
Clinomics Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Clinomics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,800.00 |
| 52 Week High | ₩6,286.67 |
| 52 Week Low | ₩1,335.00 |
| Beta | 1.57 |
| 1 Month Change | 2.62% |
| 3 Month Change | -17.05% |
| 1 Year Change | -69.63% |
| 3 Year Change | -82.24% |
| 5 Year Change | n/a |
| Change since IPO | -85.79% |
Recent News & Updates
Shareholder Returns
| A352770 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -6.3% | 2.9% | 2.7% |
| 1Y | -69.6% | 10.0% | 5.8% |
Return vs Industry: A352770 underperformed the KR Biotechs industry which returned 10% over the past year.
Return vs Market: A352770 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
| A352770 volatility | |
|---|---|
| A352770 Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A352770's share price has been volatile over the past 3 months.
Volatility Over Time: A352770's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 71 | ByungChul Kim | www.clinomics.com |
Clinomics Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company’s liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (CTCs), cell free DNA, and EV (exosome) derived from cancer tissues; Cancer-PRIME, a cancer gene analysis service for analyzing results related to precision medicine information with bioinformatics and the detection of various gene mutations; and BioViewCCBS, a scanning platform that helps in capturing cells inside the sample in 3D and in finding and analyzing CTC inside the sample.
Clinomics Inc. Fundamentals Summary
| A352770 fundamental statistics | |
|---|---|
| Market cap | ₩59.05b |
| Earnings (TTM) | -₩42.26b |
| Revenue (TTM) | ₩11.41b |
5.2x
P/S Ratio-1.4x
P/E RatioIs A352770 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A352770 income statement (TTM) | |
|---|---|
| Revenue | ₩11.41b |
| Cost of Revenue | ₩11.46b |
| Gross Profit | -₩53.97m |
| Other Expenses | ₩42.20b |
| Earnings | -₩42.26b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.29k |
| Gross Margin | -0.47% |
| Net Profit Margin | -370.43% |
| Debt/Equity Ratio | 41.4% |
How did A352770 perform over the long term?
See historical performance and comparison